imipraminoxide

Imipraminoxide (brand names Imiprex, Elepsin), or 'imipramine N-oxide', is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression.

Imipraminoxide is both an analogue and a metabolite of imipramine, and has similar effects. However, in clinical trials, imipraminoxide was found to have a faster onset of action, slightly higher efficacy, and fewer and less marked side effects, including diminished orthostatic hypotension and anticholinergic effects like dry mouth, sweating, dizziness, and fatigue.